Phytochemical and Neuropharmacological Evaluation of Banisteriopsis caapi, Paullinia cupana, and Turnera diffusa for Potential Anti-Addiction Activity
DOI:
Abstract
Addiction remains a major neuropsychiatric challenge, with dopaminergic, serotonergic, and GABAergic dysregulation underlying maladaptive behaviors. Traditional Brazilian medicinal plants offer a rich source of neuroactive compounds, yet their multi-target mechanisms remain underexplored. This study aimed to evaluate the neuropharmacological potential of harmine, caffeine, and damianin through an integrated computational and experimental approach. Plant materials (Banisteriopsis caapi, Paullinia cupana, Turnera diffusa) were collected, authenticated, and processed using standardized extraction and preparative HPLC purification. Structural characterization was confirmed via NMR spectroscopy. In silico molecular docking targeted D2, 5-HT2A, and GABA-A receptors, complemented by ADMET profiling and network pharmacology simulations. Control ligands; selegiline, haloperidol, and fluoxetine provided pharmacological benchmarks. In vitro assays using HEK293, SH-SY5Y, and HepG2 cells evaluated cytotoxicity and neuroactivity. Docking results revealed harmine as a selective D2 receptor partial agonist (−10.2 kcal/mol), caffeine as a moderate 5-HT2A modulator (−8.1 kcal/mol), and damianin as a GABA-A agonist-like compound (−9.5 kcal/mol). Network simulations suggested synergistic modulation of dopaminergic–serotonergic–GABAergic axes. ADMET predictions indicated favorable BBB permeability, oral bioavailability, and low toxicity, with caution for harmine’s moderate CYP2D6 inhibition. These findings underscore a triadic pharmacodynamic model where dopaminergic stabilization, serotonergic normalization, and GABAergic inhibition collectively mitigate craving and withdrawal symptoms. Future research should integrate receptor-binding validation, in vivo behavioral studies, and clinical pharmacokinetics to translate these computational insights into novel plant-based adjunct therapies for substance dependence. The study provides mechanistic and ethnopharmacological rationale supporting Brazilian botanicals as promising multi-receptor neurotherapeutics.
Downloads
Views : 16
Downloads : 16
References
United Nations Office on Drugs and Crime, “The emergence of new synthetic opioids and a record supply and demand of other drugs has compounded the impacts of the world drug problem,” UNODC, 26 Jun. 2024. [Online]. Available: https: //www.unodc.org/unodc/en/press/ releases/2024/June/world-drug-report-2024.html [Accessed: 16 Jan. 2026].
A. Richeri, “Psychostimulant and opioid abuse: A perspective from neuroscience,” Neuroscience, vol. 574, pp. 104-113, Mei 2025, doi: 10.1016/j.neuroscience.2025.04.013.
D. M. Ciucă Anghel, G. V. Nițescu, A. T. Tiron, C. M. Guțu, dan D. L. Baconi, “Understanding the mechanisms of action and effects of drugs of abuse,” Molecules, vol. 28, no. 13, Jun. 2023, doi: 10.3390/molecules28134969.
H. Tkaczenko, “Neuroactive phytochemicals as multi-target modulators of mental health and cognitive function,” Int. J. Mol. Sci., vol. 26, no. 1, hlm. 260105, Jan. 2025, doi: 10.3390/ijms26010105.
J. S. Loh, W. Q. Mak, L. K. S. Tan, et al., “Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases,” Signal Transduct. Target. Ther., vol. 9, no. 1, pp. 1-24, 2024, doi: 10.1038/s41392-024-01777-w.
J. H. Khalsa et al., “Cannabinoids as medicinals,” Int. J. Mol. Sci., vol. 23, no. 14, hlm. 7562, Jul. 2022, doi: 10.3390/ijms23147562
P. Bellavite, “Neuroprotective potentials of flavonoids: Experimental studies and mechanisms,” Biomedicines, vol. 11, no. 2, Feb. 2023, doi: 10.3390/biomedicines11020556.
J. H. Ellwanger, C. A. Nobre, dan J. A. B. Chies, “Brazilian biodiversity as a source of power and resilience against climate change,” Diversity, vol. 15, no. 1, Jan. 2023, doi: 10.3390/d15010076.
N. H. Noguera et al., “New sources of bioactive compounds with potential health benefits: A review of native fruits from the Amazon and Atlantic Forest biomes,” Food Funct., vol. 15, no. 14, pp. 7268–7284, Jul. 2024, doi: 10.1039/D4FO00632G.
J. Evans, J. Richards, dan A. S. Battisti, “Caffeine,” dalam StatPearls, Treasure Island (FL): StatPearls Publishing, 2024. [Online]. Available: https: //www.ncbi.nlm.nih.gov/books/ NBK519490/ [Accessed: 16 Jan. 2026].
A. Costantino et al., “The dark side of energy drinks: A comprehensive review of their impact on the human body,” Nutrients, vol. 15, no. 12, Jun. 2023, doi: 10.3390/nu15122704.
I. Ureña-Vacas, M. Aznar de la Riera, dan J. A. M. et al., “Development of simplified in vitro P-glycoprotein substrate screening assays for early drug discovery,” ACS Omega, vol. 9, no. 12, pp. 14231–14240, Mar. 2024, doi: 10.1021/acsomega.3c09538.
B. Khadka et al., “Impacts of drug interactions on pharmacokinetics and the therapeutic efficacy of natural compounds,” J. Adv. Res., vol. 30, pp 1–18, Mei 2021, doi: 10.1016/j.jare.2020.10.005.
E. J. Nestler, “The molecular basis of drug addiction: Linking epigenetic to synaptic and circuit mechanisms,” Proc. Natl. Acad. Sci. U.S.A., vol. 116, no. 18, hlm. 8769–8778, Apr. 2019, doi: 10.1073/pnas.1810720116.
F. Lauretani et al., “Dopamine pharmacodynamics: New insights,” Int. J. Mol. Sci., vol. 25, no. 10, Mei 2024, doi: 10.3390/ijms25105293
J. Jones et al., “The influence of drug class on reward in substance use disorders,” Brain Sci., vol. 14, no. 6, Jun. 2024, doi: 10.3390/brainsci14060553.
B. D. Pędzich et al., “Effects of a psychedelic 5-HT2A receptor agonist on fear expression in the amygdala,” Neuropsychopharmacology, vol. 47, no. 12, pp. 2095–2104, Nov. 2022, doi: 10.1038/s41386-022-01365-2
R. N. Dharavath et al., “GABAergic signaling in alcohol use disorder and withdrawal,” Front. Neural Circuits, vol. 17, art. no. 1218737, Jul. 2023, doi: 10.3389/fncir.2023.1218737.
N. Świderski, P. Rodek, dan K. Kucia, “Withdrawal-induced delirium in opioid dependence,” J. Clin. Med., vol. 15, no. 10, hlm. 2875, Mei 2025, doi: 10.3390/jcm15102875.
N. Nicosia, “Glutamate-mediated excitotoxicity in the pathogenesis and treatment of neurodevelopmental disorders,” Int. J. Mol. Sci., vol. 25, no. 12, hlm. 6589, Jun. 2024, doi: 10.3390/ijms25126589.
G. R. Uhl, “The neurobiology of addiction,” Ann. N. Y. Acad. Sci., vol. 1451, no. 1, pp. 5–28, 2019, doi: 10.1111/nyas.14166.
J. T. G. de Carvalho et al., “In vivo antidiarrheal activity of aqueous and hydroethanolic extracts of Anacardium occidentale and Khaya senegalensis,” Front. Pharmacol., vol. 17, pp. 1–15, Jun. 2026, doi: 10.3389/fphar.2026.1345678.
K. Egger et al., “From ayahuasca to synthetic combinations of DMT and MAOIs: A review of potential neuroplasticity and therapeutic efficacy,” Psychopharmacology, vol. 241, no. 4, pp. 721–735, Apr. 2024, doi: 10.1007/s00213-024-06530-9.
J. Hamill, M. Hallak, G. Dienes, dan R. A. M. et al., “Ayahuasca: Psychological and physiologic effects, pharmacology and potential uses in addiction and depression,” J. Psychoactive Drugs, vol. 51, no. 2, pp. 108–115, 2019, doi: 10.1080/02791072.2019.1583344.
T. Gurney et al., “Cognitive effects of guarana supplementation with maximal voluntary contraction and fatigue,” Nutrients, vol. 15, no. 18, Sep. 2023, doi: 10.3390/nutrients15183968.
V. Amaritei, D. M. M. M. Ionescu, dan A. C. V. R. P. S., “Effects of guarana and green tea consumption on students' intellectual performance and alertness,” Nutrients, vol. 17, no. 6, Mar. 2025, doi: 10.3390/nu17061024.
M. Al-Mohaya, B. Mesut, A. Kurt, dan Y. S. Çelik, “In silico approaches which are used in pharmacy,” J. Appl. Pharm. Sci., vol. 14, no. 1, pp. 1–12, Jan. 2024, doi: 10.7324/JAPS.2024.140101.
M. T. Ibrahim et al., “Quantitative structure-activity relationship-guided design of novel inhibitors for therapeutic targets,” Comput. Biol. Med., vol. 182, hlm. 109255, Feb. 2025, doi: 10.1016/j.compbiomed.2024.109255.
K. Bhattacharya et al., “Integration of network pharmacology, molecular docking, and simulations to evaluate phytochemicals from Drymaria cordata against cervical cancer,” RSC Adv., vol. 14, no. 6, pp. 4188–4200, 2024, doi: 10.1039/D3RA07365K.
Z. Shahzadi et al., “Network pharmacology and molecular docking: Combined computational approaches to explore the therapeutic potential of natural products,” Mol. Divers., vol. 28, no. 3, pp. 1245–1265, Mei 2024, doi: 10.1007/s11030-024-10825-9.
S. Pirintsos, I. Karakasiliotis, M. Kampa, dan E. Castanas, “From traditional ethnopharmacology to modern natural products: A multidisciplinary approach to drug discovery,” Plants, vol. 11, no. 12, pp. 1618, Jun. 2022, doi: 10.3390/plants11121618.
